問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Principal Investigator

蘇五洲

List

133Cases

2012-06-01 - 2014-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Study ended6Sites

2013-02-15 - 2014-04-18

Phase II

A Multicenter, Open-Label Phase 2 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

  • Condition/Disease

    Adenocarcinoma of the Lung

  • Test Drug

    E7080

Participate Sites
4Sites

Terminated4Sites

2014-10-01 - 2020-12-01

Phase III

A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer

  • Condition/Disease

    Recurrent or Progressive Metastatic Urothelial Cancer

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
5Sites

Terminated5Sites

2017-10-15 - 2021-06-11

Phase II

A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer

  • Condition/Disease

    Metastatic Non-Small Cell Lung Cancer

  • Test Drug

    Keytruda / Epacadostat

Participate Sites
6Sites

Terminated5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-10-01 - 2019-12-31

Phase III

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) – (KEYNOTE 119)

  • Condition/Disease

    Metastatic Triple Negative Breast Cancer (mTNBC)

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
5Sites

Terminated4Sites

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

邱昌芳
China Medical University Hospital-Taipei

未分科

2017-08-07 - 2021-12-31

Phase III

A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)

  • Condition/Disease

    Extensive Stage Small Cell Lung Cancer

  • Test Drug

    Keytruda

Participate Sites
8Sites

Terminated7Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2014-10-01 - 2023-03-16

Phase III

A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    MK-3475

Participate Sites
5Sites

Terminated5Sites

2013-03-01 - 2020-12-10

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-03-01 - 2012-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2019-01-01 - 2021-05-20

Phase II

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

  • Condition/Disease

    ALK-positive Advanced NSCLC

  • Test Drug

    Brigatinib

Participate Sites
5Sites

Recruiting4Sites

1 5 6 7 8 9 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB